Metamizol Auxilto (Metamizole Sodium Monohydrate)

Metamizole sodium works by inhibiting cyclooxygenase enzymes, which reduces the synthesis of prostaglandins that mediate pain and fever. In addition, it influences central pain pathways in the spinal cord and brain, contributing to its analgesic and antipyretic actions.

The dosage of Metamizol Auxilto is determined by the prescribing clinician based on the patient’s condition, age, weight, and response to therapy. Physicians tailor the regimen to achieve effective pain relief or fever control while monitoring safety.

Safety data for metamizole sodium in pregnancy and lactation are limited. The drug should only be used if the potential benefit justifies the potential risk to the fetus or infant, and this decision must be made by a qualified healthcare professional.

To place an order, submit an enquiry on the product page at gnhindia.com specifying the required quantity. GNH India works with hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details and any necessary import documentation.

Metamizole belongs to the pyrazolone class and offers strong analgesic and antipyretic effects, often comparable to high‑dose NSAIDs but without typical NSAID‑related gastric irritation. Unlike opioids, it does not produce significant respiratory depression, yet it carries a unique risk of blood‑cell disorders that must be monitored.

Metamizol Auxilto should be stored at ambient temperature, preferably below 25 °C. Keep the product in its original packaging, protect it from moisture and direct sunlight, and ensure the container is tightly closed to maintain stability.

Metamizol Auxilto is administered orally. The tablet or oral solution is taken by mouth with or without food, as directed by the prescribing physician. Proper swallowing technique and adherence to the prescribed schedule are essential for optimal effect.

The most serious adverse events linked to metamizole sodium include agranulocytosis, a potentially fatal reduction in white blood cells, and severe allergic reactions such as anaphylaxis. Patients should be monitored for signs of infection, sudden fever, or hypersensitivity, and treatment should be stopped immediately if these occur.

Metamizol Auxilto is contraindicated in individuals with a known hypersensitivity to metamizole or other pyrazolones, patients with a history of agranulocytosis, and those with severe hepatic or renal impairment where the risk outweighs benefit. It should also be avoided in pregnant or breastfeeding women unless specifically advised by a physician.